Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2016—Agena Bioscience announced the planned commercial launch of its CE-IVD marked MassArray Dx Plus assays for gene-specific mutation testing to aid in the selection of targeted therapy regimens. Agena Bioscience will introduce the first diagnostic kits in partnership with Diatech Pharmacogenetics.
January 2016—BioMérieux and Illumina announced the launch of BioMérieux EpiSeq, a next-generation sequencing service dedicated to the epidemiological monitoring and control of health care–associated infections. The EpiSeq service is the first result of the collaboration agreement signed by the two companies in November 2014.
December 2015—Luminex received FDA clearance for its Aries System and Aries HSV 1&2 Assay. Aries is a sample-to-answer molecular diagnostics platform designed to increase laboratory efficiency, ensure result accuracy, and fit into a lean laboratory environment.
December 2015—U.S. Arkray has been awarded a three-year agreement for automated urinalysis with Novation.
December 2015—InSphero has launched a 14-Day Hepatotoxicity Testing Service designed to meet increased demand for contract screening in its patent-pending 3D InSight Human Liver Microtissues. The service streamlines toxicity testing of compounds in InSphero’s 3-D liver microtissues by initiating regular screening runs on the first Tuesday of each month, at $990 per compound.
Mopec introduced the Mopec MB800 touchscreen grossing station. Its interactive touchscreen display, which highlights essential grossing station operational information, monitors formalin level, bio waste level, filter usage duration, and ventilation performance. The high-output, touch-free LED lighting system permits adjustments in color and intensity and uniformly illuminates the dissection space, which offers interchangeable grid plates and cutting board surface options.
December 2015—Roche received FDA approval for the Cobas HBV and Cobas HCV viral load tests for use on the Cobas 6800 and Cobas 8800 systems. Cobas HBV is a real-time PCR test designed to offer an expanded linear range coupled with broad coverage of all known HBV genotypes (A–H), including pre-core mutations with improved sensitivity.
December 2015—Leavitt Medical’s tissue array, BxChip, allows six needle core specimens to be placed in one block, enabling labs to reduce slide production by one-sixth. Labs that use BxChip find significant savings in the technical component.
December 2015—American Medical Technologists announced the approval of the AMT Medical Technologist (MT) exam by the California Department of Public Health, Laboratory Field Services.
December 2015—DeNovo Sciences announced that the company will operate under the name Celsee Diagnostics, effective immediately.
